| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Evgen starts trials for potential Covid treatment
StockMarketWire.com
|
Evgen Pharma has begun phase II/III trials for a treatment it claims could become a viable Covid-19 treatment if successful.
The asset, SFX-01, is being trialled with the University of Dundee to reduce the severity of acute respiratory distress syndrome.
This can include, but is not limited to, Covid-19.
Evgen Pharma made the announcement while noting the recent news from Pfizer regarding that company's progress with a vaccine and added: 'multiple approaches will be needed to curtail this virus.'
At 1:50pm: (LON:EVG) Evgen Pharma Plc share price was +0.1p at 7.9p
Story provided by StockMarketWire.com
|
|
|
|
|
|
